New combo therapy targets liver metastases in hard-to-treat cancers

NCT ID NCT04701476

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a two-part treatment for people with colorectal or non-small cell lung cancer that has spread to the liver and hasn't responded to standard therapies. The treatment combines a liver-directed procedure (TATE) that delivers a chemotherapy-like drug directly to the tumor with pembrolizumab, an immunotherapy that helps the immune system fight cancer. The goal is to see if this combination can shrink tumors and help people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China Medical University Hsinchu Hospital

    RECRUITING

    Hsinchu, Taiwan

    Contact Email: •••••@•••••

  • Chung Shan Medical University Hospital

    RECRUITING

    Taichung, Taiwan

    Contact Email: •••••@•••••

  • University of California, Irvine Medical Center

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••